Glyko Biomedical launches lysosomal screening test:
This article was originally published in Clinica
Executive Summary
Glyko Biomedical (US/Canada) has launched a lysosomal disorder screening in the US. The fluorophore-assisted carbohydrate electrophoresis (FACE) system is designed to highlight the characteristic banding patterns associated with the 25 or so lysosomal diseases that cause neuromuscular and intellectual impairment. The kit uses urine samples. Lysosomal disorders affect one in 2,000 at birth and in some cases lead to childhood death. Glyko is offering a screening service during the early marketing phase of the launch.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.